Loading clinical trials...

Epileptic Activity in Patients With Alzheimer's Disease and Lewy Body Dementia | Clinical Trials | Clareo Health

COMPLETED

Epileptic Activity in Patients With Alzheimer's Disease and Lewy Body Dementia

NCT04436341•Danish Dementia Research Centre

Summary

In the current study, the investigators will examine the extent of subclinical epileptic activity in patients with Alzheimer's disease and patients with Lewy body dementia as compared to healthy elderly controls. The participants will wear a new device called "ear-EEG", which makes it possible to record EEG for longer periods of time while at home. Furthermore, the investigators want to investigate whether there is an association between subclinical epileptic activity and the cerebral blood flow as measured with functional MRI.

Eligibility

Age

50 - 90 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Meet the criteria for probable Alzheimer's disease with amnestic presentation as described in the NIA-AA criteria (McKhann 2011)
•The diagnosis has been made by either a neurologist, psychiatrist or a geriatrician at the memory clinic at Rigshospitalet or Zealand University Hospital
•The participant is between 50 and 90 years old
•The MMSE score is between 16-28
•The participant does not wear a hearing aid
•The participant is a native Danish speaker
•The participant has at least attended school for 7 years
•The participants' hearing and vision is sufficient to participate in neuropsychological tests
•The participants' general condition of health allows that the participant can cooperate with the trial
•The participant does not suffer from psychiatric diseases (except mild depressive symptoms or mild depression) or neurological diseases that affect the brain other than Alzheimer's disease
+26 more criteria

Exclusion Criteria

•Diagnosis of epilepsy prior to the diagnosis of Alzheimer's disease was made
•Other focal pathology in the hippocampus for example hippocampal sclerosis
•The person living with the participant is not able to participate (e.g. due to a serious disease or disability) in the clinical visits or able to register behavior suspected of epilepsy
•The participant is living in a nursing home
•The participant is treated with antiepileptic medication, tricyclic antidepressants or antipsychotics
•Daily or nearly daily intake of medication known to have an anticholinergic or an adrenergic effect, which is suspected to affect the cognitive abilities or the EEG
•Large brain infarctions or more than 4 lacunar infarcts
•The participants is suffering from uncontrollable movements of the face as for example oral dyskinesia
•Diagnosis of epilepsy prior to the diagnosis of Lewy body dementia was made
•Other focal pathology in the hippocampus for example hippocampal sclerosis
+8 more criteria

Locations (2)

Gunhild Waldemar

Copenhagen, Copenhagen OE, Denmark

Troels Wesenberg Kjær

Roskilde, Denmark

Key Dates

Start Date

September 20, 2019

Primary Completion Date

September 1, 2022

Completion Date

June 1, 2023

Last Updated

March 24, 2025

Enrollment

ACTUAL participants

Conditions

Alzheimer DiseaseLewy Body DiseaseEpilepsy

Thalamus Seizure Detection With a Deep Brain Stimulator System

NCT06700356

Epilepsy; Seizure

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Epileptic Activity in Patients With Alzheimer's Disease and Lewy Body Dementia

Inclusion Criteria

Exclusion Criteria

Thalamus Seizure Detection With a Deep Brain Stimulator System

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Intracranial Investigation of Neural Circuity Underlying Human Mood